Drug:
Reaction: MALIGNANT NEOPLASM PROGRESSION
20250101 - 20251231
No. 101 - 200
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 101 | 25125731 |
US |
1 | |
Malignant neoplasm progression, |
||||
TRIPTORELIN, |
||||
| 102 | 25125758 |
JP |
2 | |
Malignant neoplasm progression, Adverse reaction, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 103 | 25125860 |
JP |
2 | |
Malignant neoplasm progression, Drug ineffective, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 104 | 25125904 |
JP |
2 | |
Malignant neoplasm progression, Drug ineffective, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 105 | 25126013 |
CA |
84 | 1 |
Hypomagnesaemia, Malignant neoplasm progression, Burning sensation, Pain in extremity, Back pain, Rash, Pruritus, Off label use, Fatigue, Dry mouth, Weight decreased, Blood pressure systolic increased, Acne, |
||||
ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, DIMENHYDRINATE, EPINEPHRINE, ADRENALINUM, ALBUTEROL SULFATE, ALBUTEROL, DIMENHYDRINATE, |
||||
| 106 | 25126014 |
US |
||
Malignant neoplasm progression, Eye pain, Blepharitis, Vision blurred, |
||||
LIFILEUCEL, ALDESLEUKIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, FLUDARABINE PHOSPHATE, MESNA, MESNA INJECTION, |
||||
| 107 | 25130175 |
1 | ||
Soft tissue sarcoma, Malignant connective tissue neoplasm, Malignant neoplasm progression, |
||||
SUNITINIB MALATE, SUNITINIB MALATE, DULOXETINE HYDROCHLORIDE, DULOXETINE, |
||||
| 108 | 25130626 |
|||
Seizure, Dizziness, Metastases to central nervous system, Malignant neoplasm progression, |
||||
BUPRENORPHINE, |
||||
| 109 | 25115740 |
JP |
68 | |
Malignant neoplasm progression, Nausea, Retching, |
||||
ZOLBETUXIMAB, FLUOROURACIL, OXALIPLATIN, LEVOLEUCOVORIN INJECTION, LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN, METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, |
||||
| 110 | 25115828 |
JP |
9 | |
Malignant neoplasm progression, Protein induced by vitamin K absence or antagonist II increased, |
||||
DURVALUMAB, TREMELIMUMAB, |
||||
| 111 | 25116124 |
EG |
56 | 2 |
Malignant neoplasm progression, Jaundice, Oedema peripheral, Localised oedema, Intercepted product prescribing error, |
||||
ABEMACICLIB, |
||||
| 112 | 25116928 |
JP |
7 | 2 |
Malignant neoplasm progression, Palmar-plantar erythrodysaesthesia syndrome, |
||||
ZOLBETUXIMAB, CAPECITABINE, OXALIPLATIN, |
||||
| 113 | 25117020 |
JP |
79 | 2 |
Malignant neoplasm progression, Cellulitis, Skin exfoliation, |
||||
ENFORTUMAB VEDOTIN, |
||||
| 114 | 25117492 |
RO |
49 | |
Malignant neoplasm progression, Metastases to liver, Metastases to adrenals, |
||||
DURVALUMAB, |
||||
| 115 | 25117893 |
CR |
38 | 2 |
Malignant neoplasm progression, Radiotherapy, Limb injury, Cutaneous vasculitis, Malignant neoplasm progression, Product use issue, |
||||
PEMBROLIZUMAB, |
||||
| 116 | 25118108 |
FR |
75 | 1 |
Lung adenocarcinoma, Malignant neoplasm progression, Diarrhoea, Agranulocytosis, Anaemia, Pyrexia, Haemorrhagic disorder, Thrombocytopenia, Transaminases increased, Off label use, Product use issue, |
||||
PEMETREXED, PEMETREXED DISODIUM, AMIVANTAMAB, CARBOPLATIN, FILGRASTIM, |
||||
| 117 | 25118663 |
DE |
||
Malignant neoplasm progression, Metastases to lung, Blood alkaline phosphatase increased, Gamma-glutamyltransferase increased, Pain, Initial insomnia, Nausea, Blood glucose increased, Blood lactate dehydrogenase increased, Aspartate aminotransferase increased, Blood calcium increased, Product use issue, |
||||
IVOSIDENIB, |
||||
| 118 | 25118720 |
US |
||
Dermatitis atopic, Malignant neoplasm progression, Product use in unapproved indication, |
||||
OSIMERTINIB, DUPILUMAB, DUPILUMAB, LIOTHYRONINE SODIUM, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, APIXABAN, |
||||
| 119 | 25119432 |
BR |
54 | 2 |
Breast cancer, Malignant neoplasm progression, Metastases to lung, Metastases to liver, Metastases to kidney, Visual impairment, Viral infection, Confusional state, Memory impairment, Decreased immune responsiveness, Influenza, Breast enlargement, Erythema, Breast pain, Pain, Renal disorder, Insomnia, Chest discomfort, Neoplasm progression, Inappropriate schedule of product administration, Lung disorder, Breast discomfort, Chest pain, Breast mass, Pruritus, Alopecia, Headache, Malaise, Paraesthesia, Drug ineffective, |
||||
ANASTROZOLE, ANASTROZOLE TABLETS, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, |
||||
| 120 | 25119520 |
JP |
45 | 2 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, PACLITAXEL, CARBOPLATIN, |
||||
| 121 | 25119575 |
JP |
9 | 2 |
Malignant neoplasm progression, Haematuria, Anaemia, |
||||
PEMBROLIZUMAB, |
||||
| 122 | 25119753 |
RU |
70 | 1 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, PEMETREXED, PEMETREXED DISODIUM, CARBOPLATIN, |
||||
| 123 | 25119868 |
PT |
39 | 1 |
Lymphadenopathy mediastinal, Malignant neoplasm progression, |
||||
PEMETREXED, PEMETREXED DISODIUM, AMIVANTAMAB, |
||||
| 124 | 25119889 |
PL |
73 | 2 |
Malignant neoplasm progression, Upper respiratory tract infection, Inflammatory marker increased, Pneumonia, Neutropenia, Chronic obstructive pulmonary disease, |
||||
LENALIDOMIDE, RITUXIMAB, RITUXIMAB, RITUXIMAB, MOSUNETUZUMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, PREDNISONE, DOXORUBICIN, |
||||
| 125 | 25120056 |
JP |
||
Malignant neoplasm progression, Renal failure, Cholangitis, |
||||
DURVALUMAB, CISPLATIN, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 126 | 25120238 |
JP |
80 | 2 |
Malignant neoplasm progression, |
||||
BEXAROTENE, |
||||
| 127 | 25120287 |
JP |
9 | 2 |
Malignant neoplasm progression, Depressed level of consciousness, Disseminated intravascular coagulation, Disorientation, Lymphoedema, Infection, |
||||
PEMBROLIZUMAB, |
||||
| 128 | 25120597 |
BE |
37 | 1 |
Malignant neoplasm progression, Sertoli cell testicular tumour, Metastases to pleura, Metastases to bone, Metastases to lung, |
||||
PAZOPANIB, PAZOPANIB HYDROCHLORIDE, PAZOPANIB, PAZOPANIB HYDROCHLORIDE, PAZOPANIB, PAZOPANIB HYDROCHLORIDE, PAZOPANIB, PAZOPANIB HYDROCHLORIDE, PACLITAXEL, PACLITAXEL, PACLITAXEL, PACLITAXEL, AXITINIB, AXITINIB, AXITINIB, AXITINIB, |
||||
| 129 | 25120662 |
JP |
67 | 2 |
Ureterolithiasis, Malignant neoplasm progression, Encephalitis, Renal disorder, Muscular weakness, Headache, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, EPLERENONE, |
||||
| 130 | 25110685 |
CA |
2 | |
Ovarian cancer, Off label use, Hydronephrosis, Malignant neoplasm progression, Colon cancer, |
||||
LETROZOLE, LETROZOLE TABLETS, |
||||
| 131 | 25110741 |
CN |
66 | 1 |
Malignant neoplasm progression, Metastases to central nervous system, Metastases to bone, Oedema peripheral, Extensor plantar response, Muscular weakness, |
||||
LEUPROLIDE ACETATE, BICALUTAMIDE, |
||||
| 132 | 25111159 |
US |
61 | |
Malignant neoplasm progression, Off label use, |
||||
NIVOLUMAB, |
||||
| 133 | 25111491 |
CA |
55 | 2 |
Seizure, Hypertension, Headache, Duodenal ulcer, Breast cancer metastatic, Malignant neoplasm progression, Osteolysis, Lymphadenitis, Chest discomfort, |
||||
LETROZOLE, FULVESTRANT, FULVESTRANT, CALCIUM, LETROZOLE, LETROZOLE TABLETS, RISEDRONATE SODIUM, ZOLEDRONIC ACID, |
||||
| 134 | 25111498 |
GB |
2 | |
Respiratory failure, Dyspnoea, Influenza, Malignant neoplasm progression, Breast cancer metastatic, Anaemia, |
||||
FULVESTRANT, RIBOCICLIB, |
||||
| 135 | 25111880 |
CA |
79 | 2 |
Blood glucose abnormal, Hepatic enzyme increased, Hormone receptor positive HER2 negative breast cancer, Malignant neoplasm progression, Drug intolerance, |
||||
ALPELISIB, ALPELISIB, FULVESTRANT, |
||||
| 136 | 25111914 |
FR |
57 | 2 |
Pyrexia, Asthenia, Myalgia, Localised melanoma, Malignant neoplasm progression, Pyrexia, Product use issue, |
||||
DABRAFENIB, DABRAFENIB, TRAMETINIB, COBIMETINIB, |
||||
| 137 | 25112162 |
US |
46 | 2 |
Hypertension, Malignant neoplasm progression, Headache, Abdominal pain, Diarrhoea, Fatigue, Stomatitis, |
||||
LENVATINIB, |
||||
| 138 | 25112439 |
JP |
6 | 2 |
Malignant neoplasm progression, Urogenital fistula, Female genital tract fistula, Thyroid disorder, Anaemia, |
||||
PEMBROLIZUMAB, |
||||
| 139 | 25112944 |
CN |
66 | 1 |
Myelosuppression, Therapy partial responder, Hypoaesthesia, Eastern Cooperative Oncology Group performance status abnormal, Malignant neoplasm progression, Product use in unapproved indication, |
||||
PEMBROLIZUMAB, CAPECITABINE, OXALIPLATIN, TRASTUZUMAB, |
||||
| 140 | 25113055 |
HR |
75 | |
Bronchiectasis, Pneumonitis, Lung consolidation, Pulmonary septal thickening, Malignant neoplasm progression, Pulmonary mass, |
||||
PEMBROLIZUMAB, IBRUTINIB, |
||||
| 141 | 25113427 |
CN |
8 | 1 |
Philadelphia positive acute lymphocytic leukaemia, Malignant neoplasm progression, Off label use, |
||||
NILOTINIB, DASATINIB, |
||||
| 142 | 25113450 |
DE |
41 | 2 |
Malignant neoplasm progression, Immune-mediated thyroiditis, Toxicity to various agents, Product use issue, Immune-mediated lung disease, Autoimmune thyroiditis, Inappropriate schedule of product administration, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, CISPLATIN, CISPLATIN, CISPLATIN, PACLITAXEL, PACLITAXEL, PACLITAXEL, PACLITAXEL, |
||||
| 143 | 25113776 |
CN |
36 | 2 |
Lymphoma, Malignant neoplasm progression, Second primary malignancy, Leukaemia, |
||||
CYTARABINE, CYTARABINE, THIOTEPA, VENETOCLAX, POLATUZUMAB VEDOTIN, |
||||
| 144 | 25113844 |
FR |
69 | |
Neutropenia, Malignant neoplasm progression, Diarrhoea, Visual impairment, Oedema, Hypertension, Oedema peripheral, Drug ineffective, |
||||
OSIMERTINIB, OSIMERTINIB, SELPERCATINIB, GEMCITABINE HYDROCHLORIDE, PEMETREXED, PEMETREXED DISODIUM, CABOZANTINIB, TRAMETINIB, CARBOPLATIN, |
||||
| 145 | 25113886 |
JP |
||
Neoplasm malignant, Malignant neoplasm progression, |
||||
CABOZANTINIB, IPILIMUMAB, NIVOLUMAB, |
||||
| 146 | 25114160 |
NO |
2 | |
Ovarian granulosa cell tumour, Malignant neoplasm progression, |
||||
LETROZOLE, LETROZOLE TABLETS, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, |
||||
| 147 | 25114441 |
PL |
57 | 1 |
Myocarditis, Malignant neoplasm progression, |
||||
PACLITAXEL, PACLITAXEL, PEMBROLIZUMAB, PEMBROLIZUMAB, CARBOPLATIN, CARBOPLATIN, ERGOCALCIFEROL, |
||||
| 148 | 25114764 |
US |
41 | 2 |
Malignant neoplasm progression, Tumour marker increased, Rash pruritic, Dry eye, Dry mouth, Dry throat, |
||||
ABEMACICLIB, |
||||
| 149 | 25114844 |
AT |
57 | 2 |
Death, Ascites, Malignant neoplasm progression, Diarrhoea, Thrombocytopenia, |
||||
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE, OXALIPLATIN, OXALIPLATIN, FLUOROURACIL, FLUOROURACIL, |
||||
| 150 | 25114990 |
81 | 1 | |
Chronic lymphocytic leukaemia, Malignant neoplasm progression, |
||||
VENETOCLAX, |
||||
| 151 | 25115087 |
US |
76 | 2 |
Transitional cell carcinoma, Malignant neoplasm progression, Off label use, |
||||
TISOTUMAB VEDOTIN, TISOTUMAB VEDOTIN, |
||||
| 152 | 25115156 |
JP |
79 | 1 |
Malignant neoplasm progression, Sepsis, Eastern Cooperative Oncology Group performance status worsened, Rash, Urinary tract infection, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, GEMCITABINE HYDROCHLORIDE, CISPLATIN, |
||||
| 153 | 25115306 |
JP |
6 | |
Malignant neoplasm progression, Recurrent cancer, |
||||
OLAPARIB, |
||||
| 154 | 25109674 |
JP |
||
Malignant neoplasm progression, Neoplasm malignant, |
||||
IPILIMUMAB, NIVOLUMAB, CABOZANTINIB, |
||||
| 155 | 25107676 |
HR |
45 | 2 |
Hepatotoxicity, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, DOXORUBICIN, |
||||
| 156 | 25107677 |
JP |
52 | 2 |
Malignant neoplasm progression, Therapy partial responder, |
||||
PEMBROLIZUMAB, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, BEVACIZUMAB, DOCETAXEL, DOCETAXEL ANHYDROUS, |
||||
| 157 | 25107711 |
JP |
37 | |
Pancytopenia, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, GEMCITABINE HYDROCHLORIDE, CARBOPLATIN, |
||||
| 158 | 25102813 |
JP |
8 | 2 |
Paraesthesia, Pruritus, Taste disorder, Malignant neoplasm progression, |
||||
ENFORTUMAB VEDOTIN, DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, |
||||
| 159 | 25102992 |
US |
72 | 1 |
Malignant neoplasm progression, Product dose omission issue, |
||||
RIPRETINIB, RIPRETINIB, |
||||
| 160 | 25103045 |
ES |
78 | 1 |
Malignant neoplasm progression, Asthenia, Arthralgia, |
||||
RIPRETINIB, RIPRETINIB, |
||||
| 161 | 25103067 |
US |
43 | 2 |
Malignant neoplasm progression, Drug ineffective, |
||||
ABEMACICLIB, ABEMACICLIB, ABEMACICLIB, LETROZOLE, LETROZOLE TABLETS, LETROZOLE, LETROZOLE TABLETS, LETROZOLE, LETROZOLE TABLETS, |
||||
| 162 | 25103938 |
US |
84 | 1 |
Malignant neoplasm progression, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, ENZALUTAMIDE, |
||||
| 163 | 25104171 |
US |
79 | |
Malignant neoplasm progression, Renal impairment, |
||||
CAPIVASERTIB, FULVESTRANT, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ANASTROZOLE, ANASTROZOLE TABLETS, ABEMACICLIB, ABEMACICLIB, CAPECITABINE, SITAGLIPTIN, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, MEGESTROL ACETATE, |
||||
| 164 | 25104177 |
IN |
||
Drug intolerance, General physical health deterioration, Bronchitis, Lower respiratory tract infection, Malignant neoplasm progression, Dyspnoea, Palpitations, |
||||
DURVALUMAB, |
||||
| 165 | 25105142 |
FR |
70 | 1 |
Malignant neoplasm progression, Pulmonary toxicity, |
||||
NIVOLUMAB, NIVOLUMAB, IPILIMUMAB, |
||||
| 166 | 25105452 |
US |
2 | |
Cervix carcinoma, Malignant neoplasm progression, |
||||
TISOTUMAB VEDOTIN, |
||||
| 167 | 25105480 |
US |
45 | 2 |
Malignant neoplasm progression, |
||||
PALBOCICLIB, |
||||
| 168 | 25105903 |
JP |
53 | 2 |
Death, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 169 | 25106082 |
JP |
74 | 2 |
Malignant neoplasm progression, |
||||
| 170 | 25106577 |
JP |
74 | 2 |
Hypoalbuminaemia, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 171 | 25106862 |
JP |
41 | |
Malignant neoplasm progression, Gene mutation identification test positive, |
||||
DURVALUMAB, DURVALUMAB, GEMCITABINE HYDROCHLORIDE, CISPLATIN, VALSARTAN, |
||||
| 172 | 25107097 |
ES |
1 | |
Renal impairment, Malignant neoplasm progression, Palmar-plantar erythrodysaesthesia syndrome, Off label use, |
||||
CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, NIVOLUMAB, |
||||
| 173 | 25107199 |
IT |
2 | |
Death, Malignant neoplasm progression, Recurrent cancer, Pain, Discomfort, Weight decreased, General physical health deterioration, |
||||
CARBOPLATIN, DURVALUMAB, TREMELIMUMAB, GEMCITABINE HYDROCHLORIDE, GEMCITABINE, |
||||
| 174 | 25107303 |
CR |
1 | |
Malignant neoplasm progression, Dermatitis bullous, Pemphigoid, Palliative care, |
||||
PEMBROLIZUMAB, |
||||
| 175 | 25107349 |
JP |
||
Malignant neoplasm progression, Renal impairment, Intentional underdose, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, |
||||
| 176 | 25107394 |
RO |
58 | |
Pneumothorax, Recurrent cancer, Renal vein thrombosis, Malignant neoplasm progression, Radiation necrosis, Lung neoplasm, Lung consolidation, |
||||
PEMBROLIZUMAB, PEMETREXED, PEMETREXED DISODIUM, CARBOPLATIN, |
||||
| 177 | 25107589 |
JP |
54 | 2 |
Fulminant type 1 diabetes mellitus, Malignant neoplasm progression, Diabetic ketoacidosis, Tubulointerstitial nephritis, Immune-mediated hypothyroidism, Immune-mediated hypophysitis, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, DENOSUMAB, |
||||
| 178 | 25098310 |
US |
75 | |
Malignant neoplasm progression, |
||||
NIVOLUMAB, |
||||
| 179 | 25098533 |
US |
||
Malignant neoplasm progression, |
||||
TEBENTAFUSP, |
||||
| 180 | 25098573 |
TH |
62 | 1 |
Malignant neoplasm progression, |
||||
IRINOTECAN HYDROCHLORIDE, |
||||
| 181 | 25098635 |
CA |
74 | |
Malaise, Malignant neoplasm progression, Drug ineffective, |
||||
ACALABRUTINIB, ACALABRUTINIB, |
||||
| 182 | 25098960 |
JP |
79 | 2 |
Hemiplegia, Steroid withdrawal syndrome, Dysarthria, Immune-mediated myocarditis, Addison^s disease, Malignant neoplasm progression, Decreased appetite, Pleural effusion, Adrenocorticotropic hormone deficiency, Depression, Malaise, |
||||
CABOZANTINIB, IPILIMUMAB, NIVOLUMAB, NIVOLUMAB, |
||||
| 183 | 25099019 |
US |
1 | |
Febrile neutropenia, Malignant neoplasm progression, Myelosuppression, Thrombocytopenia, Drug ineffective for unapproved indication, |
||||
CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, TEMOZOLOMIDE, ETOPOSIDE, |
||||
| 184 | 25099204 |
US |
69 | |
Malignant neoplasm progression, Illness, |
||||
CETUXIMAB, |
||||
| 185 | 25099735 |
CA |
49 | 2 |
Asthenia, Confusional state, Fall, Hypercalcaemia, Malignant neoplasm progression, Metastases to liver, |
||||
CAPECITABINE, FAM-TRASTUZUMAB DERUXTECAN-NXKI, TUCATINIB, OLANZAPINE, OLANZAPINE, OLANZAPINE, ANASTROZOLE, ANASTROZOLE TABLETS, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, EXTENDED PHENYTOIN SODIUM, FUROSEMIDE, HALOPERIDOL DECANOATE, LETROZOLE, LETROZOLE TABLETS, LORAZEPAM, MELATONIN, METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PHENYTOIN SODIUM, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, GOSERELIN, GOSERELIN, GOSERELIN, GOSERELIN, |
||||
| 186 | 25100081 |
JP |
73 | 2 |
Malignant neoplasm progression, Immune-mediated hypothyroidism, Thyroiditis, Diarrhoea, |
||||
PEMBROLIZUMAB, |
||||
| 187 | 25100361 |
JP |
8 | 1 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, GEMCITABINE HYDROCHLORIDE, CISPLATIN, |
||||
| 188 | 25100407 |
US |
34 | 2 |
Malignant neoplasm progression, |
||||
TISOTUMAB VEDOTIN, |
||||
| 189 | 25100451 |
US |
48 | 2 |
Malignant neoplasm progression, Product use issue, Off label use, |
||||
TUCATINIB, CAPECITABINE, |
||||
| 190 | 25100522 |
CN |
55 | |
Hydrocephalus, Malignant neoplasm progression, |
||||
ABEMACICLIB, ANASTROZOLE, ANASTROZOLE TABLETS, |
||||
| 191 | 25100532 |
IT |
2 | |
Death, Neoplasm recurrence, Malignant neoplasm progression, Pain, Medication error, Weight decreased, |
||||
GEMCITABINE HYDROCHLORIDE, DURVALUMAB, TREMELIMUMAB, CARBOPLATIN, |
||||
| 192 | 25100593 |
US |
71 | 2 |
Dehydration, Cholecystitis, Fluid intake reduced, Decreased appetite, Weight decreased, Malignant neoplasm progression, |
||||
LENVATINIB, LENVATINIB, |
||||
| 193 | 25100666 |
JP |
8 | 1 |
Hepatic enzyme increased, Malignant neoplasm progression, Adrenal insufficiency, Decreased appetite, |
||||
PEMBROLIZUMAB, |
||||
| 194 | 25100773 |
GB |
73 | 1 |
Endocarditis, Diffuse large B-cell lymphoma, Malignant neoplasm progression, |
||||
RITUXIMAB, CISPLATIN, DEXAMETHASONE SODIUM PHOSPHATE, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, GEMCITABINE HYDROCHLORIDE, VINCRISTINE SULFATE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, PREDNISONE, |
||||
| 195 | 25101001 |
JP |
68 | 1 |
Colitis, Neck mass, Malignant neoplasm progression, Thyroid disorder, |
||||
CABOZANTINIB, IPILIMUMAB, NIVOLUMAB, NIVOLUMAB, |
||||
| 196 | 25101057 |
AT |
||
Electrocardiogram QT prolonged, Malignant neoplasm progression, Off label use, |
||||
IVOSIDENIB, |
||||
| 197 | 25101094 |
HK |
1 | |
Cognitive disorder, Death, Malignant neoplasm progression, Fatigue, Hot flush, Insomnia, Night sweats, Respiratory disorder, |
||||
TRIPTORELIN PAMOATE, |
||||
| 198 | 25101283 |
GB |
2 | |
Respiratory failure, Dyspnoea, Influenza, Malignant neoplasm progression, Breast cancer metastatic, Anaemia, |
||||
RIBOCICLIB, FULVESTRANT, |
||||
| 199 | 25101345 |
FR |
67 | |
Malignant neoplasm progression, Malignant transformation, Neuroendocrine carcinoma, |
||||
OSIMERTINIB, |
||||
| 200 | 25101493 |
ES |
50 | 1 |
Cervical spinal stenosis, Diverticulum intestinal, Hypertrophy, Abdominal distension, Flank pain, Malignant neoplasm progression, Dizziness, Neuralgia, Nerve compression, Mucosal toxicity, Headache, Diarrhoea, Mucosal inflammation, Mouth ulceration, Hypertension, |
||||
EVEROLIMUS, EVEROLIMUS TABLETS, LENVATINIB, CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28